US Patent Number
Disclosed herein are nucleic acid molecules comprising a nucleotide sequence of sVEGF-2, proteins encoded by those sequences and antibodies that bind to the protein. Also disclosed are methods for inhibiting or enhancing expression or activity of sVEGFR-2 and methods for inhibiting graft rejection, particularly cornea graph rejection. Also described are methods for inhibiting lymphangiogenesis and lymphatic endothelial cell proliferation by administering an effective amount of sVEGFR-2 and methods for treating lymphedema by inhibiting the activity of sVEGFR-2.
University of Kentucky Research Foundation, Lexington, KY (US)
Ambati, Jayakrishna and Albuquerque, Romulo J., "sVEGFR-2 and its Role in Lymphangiogenesis Modulation" (2014). Ophthalmology and Visual Science Faculty Patents. 9.